David Baldwin, MD, FRCP is an Honorary Professor of Medicine and Consultant Physician at Nottingham University Hospitals NHS Trust, specializing in lung cancer and mesothelioma and interventional procedures. He is also the Chair of the National Cancer Research Institute Screening, Prevention and Early Diagnosis Group, the Chair of the Clinical Expert Group for Lung Cancer, NHS England and Clinical Director of the East Midlands Cancer Alliance.
Prof. Baldwin has held the positions of Honorary Secretary of the British Thoracic Society, Clinical Lead on the NICE Lung Cancer Guideline Development Group and Chair of the Quality Standards Group on Lung Cancer.
Speaking on the epidemiology, diagnosis and staging of lung cancer and the use of CT screening
Prof. Baldwin has published over 220 peer-reviewed papers, specifically focusing on on CT screening and lung cancer epidemiology. He is currently the lead respiratory physician on the UK CT lung cancer screening trial (UKLS) funded by the NIHR HTA programme, is an investigatory in a number of other studies including MesoVATS, Fragmatic and BOOST, and is a principal investigator for NUH on the Sputnik trial and SABRTooTH trials.